Treatment with dietary trans10cis12 conjugated linoleic add causes isomerm-specific insulin resistance in obese men with the metabolic syndrome
Treatment with dietary trans10cis12 conjugated linoleic add causes isomerm-specific insulin resistance in obese men with the metabolic syndrome
复制标题
DOI：
10.2337/diacare.25.9.1516
复制
发表时间：
2002-09-01
期刊：
影响因子：
16.2
通讯作者：
Vessby, B
中科院分区：
文献类型：
--
作者：
Risérus, U;Arner, P;Vessby, B
目的-共轭亚油酸（CLA）是一类在某些动物中具有抗肥胖和抗糖尿病作用的膳食脂肪酸。trans - 10cis12 (t10c12) CLA异构体似乎引起了这些影响，包括改善胰岛素敏感性。这种异构体特异性效应是否会发生在人类身上尚不清楚。本研究的目的是研究t10c12 CLA或商用CLA混合物是否可以改善有代谢综合征体征的肥胖男性的胰岛素敏感性、脂质代谢或身体组成。研究设计和方法：在一项随机、双盲对照试验中，腹部肥胖男性（n = 60）接受3.4 g/d CLA（异构体混合物）、纯化t10c12 CLA或安慰剂治疗。在治疗前和治疗后1周评估血糖-高胰岛素钳、血清激素、血脂和人体测量。结果：两组之间的基线代谢状态相似。出乎意料的是，与安慰剂相比，t10c12 CLA增加了胰岛素抵抗（19%,P < 0.01）和血糖（4%,P < 0.001），降低了高密度脂蛋白胆固醇（-4%,P < 0.01），而体脂、矢状腹直径和体重与基线相比下降，但与安慰剂相比差异不显著。与安慰剂相比，CLA混合物没有改变葡萄糖代谢、体成分或体重，但降低了高密度脂蛋白胆固醇（-2%;P < 0.05）；结论：这些结果揭示了CLA在腹部肥胖人群中重要的异构体特异性代谢作用。cla诱导的胰岛素抵抗以前只在脂肪营养不良小鼠中被描述过。考虑到在肥胖人群中使用cla补充剂，重要的是要。澄清这些结果的临床结果，但它们也为特定膳食脂肪酸作为人类胰岛素抵抗调节剂的作用提供了生理学上的见解。
OBJECTIVE- Conjugated linoleic acid (CLA) is a group of dietary fatty acids with antiobesity and antidiabetic effects in some animals. The trans10cis12 (t10c12) CLA isomer seems to cause these effects, including improved insulin sensitivity. Whether such isomer-specific effects occur in humans is unknown. The aim of this Study was to investigate whether t10c12 CLA or a commercial CLA mixture could improve insulin sensitivity, lipid metabolism, or body-composition in obese men with signs of the metabolic syndrome.RESEARCH DESIGN AND METHODS- in a randomized, double-blind controlled trial, abdominally obese men (n = 60) were treated with 3.4 g/day CLA (isomer mixture), purified t10c12 CLA, or placebo. Euglycemic-hyperinsulinemic clamp, serum hormones, lipids, and anthropometry were assessed before and after 1 weeks of treatment.RESULTS- Baseline metabolic status was similar between groups. Unexpectedly, t10c12 CLA increased insulin resistance (19%; P < 0.01) and glycemia (4%; P < 0.001) and reduce HDL cholesterol (-4%;P < 0.01) compared with placebo, whereas body fat, sagittal abdominal diameter, and weight decreased versus baseline,but the difference was not significantly different from placebo. The CLA mixture did not change glucose metabolism, body composition, or weight compared with placebo but lowered HDL cholesterol (-2%; P < 0.05);CONCLUSIONS- These results reveal important isomer-specific metabolic actions of CLA in abdominally obese humans. A CLA-induced insulin resistance has previously been described only in lipodystrophic mice. Considering the use of CLA-supplements among obese individuals, it is important to. clarify the clinical consequences of these results, but they also provide physiological insights into the role of specific dietary fatty acids as modulators of insulin resistance, in humans.